Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29407166 | 0.92 | ACE (0.54) | MMEACEENPEP | |
| SCHEMBL30417812 | 0.91 | MME (0.59) | OPRD1OPRM1MMEACE | |
| SCHEMBL30414144 | 0.91 | MME (0.59) | OPRD1OPRM1MMEACE | |
| SCHEMBL30400950 | 0.89 | MME (0.53) | BACE1BACE2MMEACE | |
| SCHEMBL29666764 | 0.89 | ACE (0.56) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL29860725 | 0.88 | OPRM1 (0.53) | BACE1BACE2OPRD1OPRM1OPRK1 | |
| SCHEMBL30483948 | 0.88 | BACE1 (0.55) | BACE1BACE2OPRD1OPRM1OPRK1 | |
| SCHEMBL31195269 | 0.88 | MME (0.50) | OPRD1OPRM1MMEACEENPEP | |
| SCHEMBL30123042 | 0.87 | MME (0.58) | MMEACEENPEP | |
| SCHEMBL29877007 | 0.87 | MME (0.55) | BACE1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | disclosed |